New drugs, therapeutic strategies, and future direction for the treatment of Pulmonary Arterial Hypertension.
CURRENT MEDICINAL CHEMISTRY(2019)
摘要
Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.
更多查看译文
关键词
Pulmonary arterial hypertension,macitentan,riociguat,selexipag,initial combination therapy,gene therapy,serotonin,inflammation,immunity,metabolism,pulmonary arterial denervation
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要